Medistim ASA (STU:MD1) ROCE %: 39.92% (As of Mar. 2026)

What is Medistim ASA ROCE %?

Medistim ASA STU:MD1 -0.99% 96 ROCE % is 39.92% as of Mar. 2026. GuruFocus rates STU:MD1 with a GF Score™ of 96/100 and a GF Value™ of €22.51. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medistim ASA's annualized ROCE % for the quarter that ended in Mar. 2026 was 39.92%.

Medistim ASA (STU:MD1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medistim ASA ROCE % Related Terms

Medistim ASA ROCE % Historical Data

* Premium members only.

The historical data trend for Medistim ASA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medistim ASA ROCE % Chart

Medistim ASA Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

38.22

40.75

32.63

30.35

43.11

Medistim ASA Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															50.30	49.50	37.68	34.87	39.92

96GF Score

Medistim ASA STU:MD1

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Medistim ASA ROCE % Calculation

Medistim ASA's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	18.004	/	( ( (48.937 - 9.138)	+	(55.819 - 12.101) )	/ 2 )
	=	18.004	/	( (39.799	+	43.718)	/ 2 )
	=	18.004	/	41.7585
	=	43.11 %

Medistim ASA's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	18.6	/	( ( (55.819 - 12.101)	+	(61.068 - 11.61) )	/ 2 )
	=	18.6	/	( ( 43.718	+	49.458 )	/ 2 )
	=	18.6	/	46.588
	=	39.92 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 39.92% mean?

Medistim ASA (STU:MD1) has a ROCE % of 39.92% as of Mar. 2026.

Is Medistim ASA's ROCE % too high?

Medistim ASA's current ROCE % is 39.92%. The Medical Devices & Instruments industry median ROCE % is 2.23. Medistim ASA's value of 39.92% is 1690.1% above this industry median. Overall, Medistim ASA has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.

How does Medistim ASA's ROCE % compare to ABT and SYK?

Medistim ASA's ROCE % of 39.92% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Medistim ASA's value of 39.92% is 1690.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medistim ASA's current ROCE % of 39.92% is 1690.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medistim ASA's current ROCE % is 39.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Medistim ASA stock overvalued right now?

Medistim ASA (STU:MD1) has a current ROCE % of 39.92%. The stock's GF Value™ is €22.51, compared to a current price of €20.10 — trading 10.7% below its estimated fair value. The current ROCE % is 39.92% and 1690.1% above the Medical Devices & Instruments industry median of 2.23. Medistim ASA's overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Medistim ASA (STU:MD1), the current ROCE % is 39.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medistim ASA (STU:MD1) Overvalued in 2026?

Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued. The current stock price of €20.10 is trading 10.7% below its estimated GF Value™ of €22.51.

Key valuation signals for STU:MD1:

ROCE %: 39.92%
GF Value™: €22.51 vs. price of €20.10 (10.7% below fair value)
GF Score™: 96/100 with 1 warning sign
Industry Position: 1690.1% above the Medical Devices & Instruments median

No single metric tells the full story. See the STU:MD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medistim ASA Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies OSL:GENT OSL:OBSRV OSL:LIFE ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA STE ZBH XSWX:SOON SHSE:688271 LSE:SN.PEN TSE:7733

Other Exchanges MEDIO:Sweden MEDI:Norway 0OCD:UK MD1:Germany

Address Okernveien 94, Oslo, NOR, 0579

Website https://www.medistim.com

Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.

96GF Score

Get the complete analysis for STU:MD1

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.10

Price

€22.51

GF Value

View STU:MD1 Analysis

See ROCE % data for all stocks →